Sign Out
NESP is indicated for the treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis.
Anemia with myelodysplastic syndrome.
Precautions related to Indications: Anemia with myelodysplastic syndrome: The efficacy and safety of NESP have not been established in patients who are in the intermediate-2 or high risk categories under the IPSS Note).
Patients indicated for NESP should be selected based on a full knowledge of the description in "Pharmacology: Clinical Studies under Actions", including serum erythropoietin concentration in patients enrolled in clinical studies, as well as adequate understanding of the efficacy and safety of NESP and reference to the academic guidelines and other relevant updates.
Note) International Prognostic Scoring System.
Continue with Google